Welcome to our dedicated page for GT Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on GT Biopharma stock.
GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Leveraging its proprietary NK cell engager (TriKE) platform technology, the company is dedicated to advancing innovative therapeutics in the United States. With a primary focus on cancer treatment, GT Biopharma's TriKE platforms offer promising solutions for hematologic malignancies, sarcoma, and solid tumors.
GT Biopharma (NASDAQ: GTBP) announced the immediate appointment of Manu Ohri as its new Chief Financial Officer (CFO). With over 25 years of management and finance experience, Ohri's previous roles include CFO for various public companies and management consultant in the biotech sector. His expertise is expected to strengthen the company's financial management and enhance communication with capital markets. GT Biopharma recently reported positive data from first-in-human trials of its TriKE® platform, marking a significant milestone in its clinical development efforts.
GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that Dr. Greg Berk, President of R&D and Interim CEO, will participate in a Fireside Chat at the B. Riley Securities' Virtual Oncology Conference. The event is scheduled for January 27, 2022, at 9:30 A.M. EST. This conference will showcase innovations in immuno-oncology, particularly focusing on GT Biopharma's proprietary TriKE® NK cell engager platform, which aims to enhance the cancer-fighting abilities of natural killer cells. Further details and webcast information are available.
GT Biopharma, Inc. (NASDAQ: GTBP) has announced the approval of equity compensation awards to key employees as inducements to join the company, as per Nasdaq Listing Rule 5635(c)(4). The awards include options for Gavin Choy (227,500 shares at $3.05 each), Leslie Bransfield (75,000 shares at $3.05), and a stock award for Kathy Quandt (50,000 shares). The options have a 10-year term, with specific vesting schedules. GT Biopharma focuses on developing immuno-oncology therapies utilizing its TriKE® platform, licensed from the University of Minnesota.
GT Biopharma, Inc. (NASDAQ: GTBP) announced the availability of its mini-poster presentation at the ESMO Immuno-Oncology Congress 2021 in Geneva, Switzerland, from December 8-11, 2021. The presentation focuses on GTB-5550, a dual camelid nanobody that targets the B7-H3 molecule, showing effective NK cell activation against various tumors, including enzalutamide-resistant prostate cancer. The company is advancing its TriKE® technology platform, and GMP production of GTB-5550 has begun, indicating significant progress in its clinical pipeline.
GT Biopharma (NASDAQ: GTBP) announced the acceptance of an abstract for presentation at the ESMO Immuno-Oncology Congress 2021, scheduled for December 8-11, 2021, in Geneva, Switzerland. The e-Poster titled 'Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies' emphasizes the potential of their TriKE® technology. Full abstracts will be published on December 2, 2021, at 12:00 pm CET, and the company will share its poster on its website during the conference.
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, will host a Management Update Conference Call on November 30, 2021, at 4:30 PM ET. The call features Michael Breen, Executive Chairman, and Dr. Greg Berk, Chief Medical Officer. Participants can join via a live webcast or by phone at toll-free 1-877-407-9039 (international: 1-201-689-8470). An archived replay will be available on the company’s website post-event. The conference will discuss the company’s innovative TriKE platform, focused on enhancing NK cell cancer therapies.
GT Biopharma (NASDAQ: GTBP) reported its third quarter 2021 results, highlighting significant advancements in its TriKE platform. Key achievements include securing new intellectual property protecting the platform through 2036 and demonstrating proof of concept safety data from its Phase 1 clinical trial. The Company reported cash and cash equivalents of $35.8 million as of September 30, 2021, up from $7 million at the end of 2020. However, R&D expenses surged to $1 million from $84,000 in Q3 2020, reflecting increased clinical trial activity. The net loss was $5.5 million, compared to a $2.9 million loss in the prior year.
GT Biopharma, Inc. (NASDAQ: GTBP) announced a major restructuring of its executive management team on November 8, 2021. Chairman and CEO Anthony Cataldo and CFO Michael Handelman will depart to pursue other interests. The Board appointed Dr. Gregory Berk as interim CEO and Dr. Gavin Choy as acting CFO. Michael Breen becomes Executive Chairman and oversees the transition. The company is seeking permanent replacements for the CEO and CFO roles. GT Biopharma focuses on developing immunotherapies based on its proprietary TriKE® platform aimed at transforming cancer treatment.
GT Biopharma (NASDAQ: GTBP) announced that Dr. Jeffrey Miller presented at the ESMO Congress 2021, showcasing the efficacy of camelid TriKEs in targeting solid tumors. The Company plans to advance these TriKEs into clinical trials in 2022. They also provided updates on the ongoing Phase 1 clinical trial of GTB-3550, which has shown safety and early anti-leukemic activity in patients with AML and MDS. The treatment was well tolerated, with one patient experiencing a mild cytokine release syndrome event.
GT Biopharma announced that Dr. Jeffrey Miller will present updated positive Phase 1 safety data for the GTB-3550 TriKE trial at the ESMO Congress 2021. The trial focuses on treating relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS), with future plans for solid tumors. The presentation will highlight how GTB-3550 activates IL-15 in NK cells. Additionally, the company is advancing GTB-3650 into IND-enabling studies, which promises enhanced efficacy over GTB-3550 due to its novel camelid antibody technology and strong preclinical data.
FAQ
What is the current stock price of GT Biopharma (GTBP)?
What is the market cap of GT Biopharma (GTBP)?
What is GT Biopharma Inc. focused on?
What is GT Biopharma's proprietary platform technology?
What types of cancers does GT Biopharma's TriKE platforms target?
What stage is GT Biopharma currently in?
What sets GT Biopharma apart in the biopharmaceutical industry?
